In the current study, significantly higher levels of urinary biomarkers albumin, β2 microglobulin, and NGAL in the torsemide group suggest that there may be a greater degree of renal tubular injury and/or dysfunction in patients who are treated with torsemide compared with furosemide, though the clinical significance of these differences in the chronic HF population is unknown. The gene discussed is ALB; the disease is hydrops fetalis.